Mankind Pharma delivered strong Q2 2026 results with diluted normalized EPS of ₹12.38, representing a 16.79% quarter-on-quarter growth from ₹10.60 in Q1. The company reported total revenue of ₹3,697.16 crore, marking a 3.55% increase from Q1's ₹3,570.35 crore. However, net income declined 21.72% year-on-year to ₹511.51 crore compared to ₹653.47 crore in Q2 FY25. Operating income grew 11.37% QoQ to ₹699.51 crore, while total operating expenses increased 29.50% YoY to ₹2,997.65 crore. The company's net income before taxes rose 15.45% QoQ to ₹624.02 crore, indicating improved operational efficiency despite revenue challenges.
According to The Times of India, Somil Mehta, Head of Retail Research at Mirae Asset Sharekhan, has identified four top stocks to buy on July 7, 2026. The recommendations include Mankind Pharma, Bajaj Auto, UNO Minda, and Jubilant FoodWorks. These selections are based on technical analysis and chart patterns showing potential for upward movement. Recent brokerage updates show fresh views on Mankind Pharma, Trent, Titan, Jubilant FoodWorks, and HDFC AMC, with Mankind Pharma receiving an Add rating with target price of ₹2,821. The latest reports confirm that brokerages have issued fresh views on these stocks alongside commentary on India hotels and other sectors.
As reported by The Times of India, Mankind Pharma is recommended as a buy in the range between ₹2,541-₹2,542 with a stop loss at ₹2,450 and target of ₹2,650. The stock shows higher top and higher bottom formation above the 20 Weekly exponential moving average on the weekly timeframe. On the daily chart, the price is forming a triangle pattern expecting to give breakout in the upside direction as buyers consistently defend lower price levels. The momentum indicator shows positive crossover indicating strength in the chart, with key resistance at ₹2,600 and key support at ₹2,475. Recent brokerage analysis highlights the company's strategy for defensible products, moving into less-crowded markets, with chronic therapy having ~40% share and a new biologics platform backed by a field force scaling every deal. The latest reports emphasize that gains build in slowly, returns still ahead for this pharmaceutical stock.
According to The Times of India, Bajaj Auto is recommended as a buy in the range between ₹10,036-₹10,037 with a stop loss at ₹9,600 and target of ₹10,500. The stock shows strong support from important demand zone area which aligns with 20 Weekly exponential moving average on the weekly timeframe. The structural alignment shows buyers are active at this support area. On the daily chart, the stock shows small range breakout by taking support of 40 DEMA. The momentum indicator shows positive crossover above zero line indicating strong bullish strength, with key resistance at ₹10,250 and major support holding at ₹9,750. Recent brokerage updates show a breakout above the ₹957–968 resistance zone, confirming a fresh momentum breakout and activating an upside measured-move target of ₹1,250–1,260. The latest reports confirm that breakout above the confluence of resistance at ₹1,894–1,951 supports an upside target of ₹2,650-2,660.
According to latest brokerage reports, HDFC AMC is showing strong technical momentum with a breakout above the ₹957–968 resistance zone confirming a fresh momentum breakout and activating an upside measured-move target of ₹1,250–1,260. The stock shows breakout opens the way for an upside objective of ₹3,580, with the breakout structure projecting an upside objective of ₹13,390–13,400. Recent brokerage analysis maintains a Buy rating with target price of ₹830, up from the previous ₹790, citing that the stock is pivoting well with growth to follow. The momentum indicators show positive crossover above zero line indicating strong bullish strength. The latest reports confirm that move back above the 200DMA reinforces the late-June breakout, supporting the positive technical outlook for this asset management company.
